Larry Sexton
Psychiatric/Mental Health · Augusta, MENPI 1396849980
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 676 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 676 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $5K from 10 others
What the payments were for
- Food & beverage$14,78999%
- Education$2211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 70 | $2,116 |
| Alkermes, Inc. | 88 | $1,949 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 72 | $1,598 |
| Teva Pharmaceuticals USA, Inc. | 60 | $1,487 |
| AbbVie | 66 | $1,458 |
| Otsuka America Pharmaceutical, Inc. | 71 | $1,400 |
| Neurocrine Biosciences, Inc. | 54 | $985 |
| Lundbeck LLC | 40 | $923 |
| Sunovion Pharmaceuticals Inc. | 71 | $902 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $710 |
| Axsome Therapeutics, Inc. | 13 | $543 |
| Vanda Pharmaceuticals Inc. | 14 | $412 |
| E.r. Squibb & Sons, L.L.C. | 10 | $323 |
| Braeburn Inc. | 5 | $100 |
| Corium, LLC | 4 | $73 |
| Ironshore Pharmaceuticals Inc. | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,010 in reported general payments places this provider in the 95th percentile of 192 psychiatric/mental health providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 20 | $259,000 |
| IngrezzaValbenazine Tosylate | 27 | $221,329 |
| Austedo XrDeutetrabenazine | 37 | $211,071 |
| VraylarCariprazine Hcl | 129 | $183,935 |
| CaplytaLumateperone Tosylate | 109 | $172,966 |
| AristadaAripiprazole Lauroxil | 54 | $167,869 |
| Invega SustennaPaliperidone Palmitate | 44 | $153,837 |
| Abilify MaintenaAripiprazole | 17 | $47,055 |
| RexultiBrexpiprazole | 27 | $46,308 |
| SeroquelQuetiapine Fumarate | 20 | $34,550 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $18,802 |
| Aripiprazole | 64 | $15,126 |
| Lurasidone Hcl | 58 | $14,850 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $13,032 |
| Olanzapine OdtOlanzapine | 43 | $8,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $1,487 | $470,07157 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $985 | $221,32927 claims |
| AbbVieVraylar | $1,458 | $183,935129 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,598 | $172,966109 claims |
| Alkermes, Inc.Aristada | $1,949 | $167,86954 claims |
| Johnson & JohnsonInvega Sustenna | $2,116 | $153,83744 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,400 | $93,36344 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $710 | $20,07547 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 192 psychiatric/mental health providers in Maine.
Other psychiatric/mental health in Augusta
- Priscilla YoungAugusta$820
- Marianne TarrazaScarborough$22K
- Kelly BraggMadison$21K
- Michelle ChmeleckiPortland$12K
- Bethney SeifertBangor$8K
- Janet ZalanskasWaterville$6K
- Susan MartinScarborough$6K
- Samuel KingsleyScarborough$6K
- Alison CameronScarborough$5K
- Marta HallWaterville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.